CARTISTEM
Asset
Allogeneic umbilical cord blood-derived mesenchymal stem cells with hyaluronate hydrogel to regenerate cartilage and reduce inflammation
- Stage
- Phase 3
- Modality
- Cell therapy
- Target
- Inflammation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Knee cartilage defects
Phase 3, Recruiting, NCT07339111, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.